Success Story: NIW Approval for a Biomedical Science Researcher Advancing Cancer Therapy

Client’s Testimonial:

“Thank you very much for your assistance throughout my NIW petition process. I truly appreciate all of your support, and I am very grateful for the successful approval of my I-140.”

On July 14th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Research Assistant in the Field of Biomedical Science (Approval Notice).

General Field: Biomedical Science

Position at the Time of Case Filing: Graduate Research Assistant

Country of Origin: China

State of Residence at the Time of Filing: Kentucky

Approval Notice Date: July 14th, 2026

Processing Time: 23 months, 14 days

Case Summary:

Developing more effective treatments for cancer remains one of the most pressing priorities in biomedical science, particularly as drug resistance continues to limit the long-term success of many therapies. Seeking to contribute to this challenge, the client pursued an EB-2 National Interest Waiver (NIW) based on research focused on investigating the molecular mechanisms underlying drug resistance in cancer cells and identifying key pathways and biomarkers that could lead to more effective cancer-targeted therapies, novel drugs, and nanomedicines. At the time of filing, the client was conducting biomedical science research and our legal team demonstrated that this work addresses an area of substantial merit and national importance because of its potential to improve cancer treatment and advance biomedical innovation.

To establish that the client was well positioned to continue advancing this nationally important endeavor, we presented a comprehensive record of scholarly achievements and explained how each piece of evidence reflected growing recognition within the scientific community. Rather than relying on numerical metrics alone, we demonstrated how the client's research had begun influencing ongoing work in cancer biology, nanomedicine, and drug development.

The client's credentials included:

• M.S. in biology
• Research focused on uncovering the molecular mechanisms of cancer drug resistance and developing targeted therapies and nanomedicines.
• 5 peer-reviewed journal articles (including 1 first-authored publication) and 1 pre-print.
• 59 citations to published research.
• Completion of at least 4 peer reviews for scholarly publications.
• Research supported by funding from the U.S. Army Engineer Research and Development Center (ERDC) and the National Institutes of Health (NIH).

These accomplishments were analyzed in the context of the NIW framework rather than presented as achievements standing alone. For example, the publication record demonstrated sustained contributions to biomedical science, while the citation evidence showed that independent researchers had relied upon the client's findings in subsequent investigations. The petition also emphasized that several publications had performed exceptionally well relative to other papers published during the same period, providing additional objective evidence that the client's work had gained meaningful recognition within the field. Likewise, the client's peer-review service illustrated that established journals trusted the client's scientific judgment, an important indicator that the research community recognized the client's expertise. Funding from prominent U.S. agencies further reinforced that the research addressed nationally significant priorities involving public health and biomedical innovation.

By organizing the evidence into a clear legal framework, we demonstrated that the client's education, research experience, scholarly publications, independent citations, peer-review activities, and federally supported research collectively established the client's ability to continue making valuable contributions to biomedical science. USCIS ultimately approved the I-140 National Interest Waiver petition, recognizing that the client's continued work on overcoming cancer drug resistance has the potential to advance therapies that could benefit patients while supporting the United States' long-term scientific and technological leadership.